The Association of Diversity in Clinical Trials (AOD) has announced a new partnership agreement with Black Women in Clinical Research (BWICR) allowing their 15,000 members an opportunity to participate in AOD benefits. The mission of the AOD is to establish standards and best practices for the clinical trials industry to improve the representation of diverse participants in clinical trials through the development, integration, and monitoring of quality and consistent diversity methodology across the research industry.
Danielle Mitchell, CEO of BWICR, stated, "The mission of the AOD meets our corporate goals in being a part of standardizing best practices for professionals and bringing training and certification forward in a structured and accessible way for our members. This commitment is exciting and will bring value to our industry as a whole."
Diana Foster, PhD, president of the AOD, credits Mitchell's story of having been blocked from entry into clinical research as the impetus behind her organization's mission.
BLACK WOMEN IN CLINICAL RESEARCH JOINS THE ASSOCIATION OF DIVERSITY IN CLINICAL TRIALS AS A SUPPORTING PARTNER BRINGING 15,000 MEMBERS TO PARTICIPATE IN AOD MEMBERSHIP. (2023, June 21). Cision PR Newswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.